: Sanofi COVID-19 vaccine to cost below €10 and drug ingredients IPO planned within months, its France chief says

Sanofi’s experimental COVID-19 vaccine will cost less than €10 per shot, the pharma company’s France chief said Saturday.

Eric Piermont/Agence France-Presse/Getty Images

Sanofi SAN, +2.60% stock rose on Monday, after a senior executive said the French pharmaceutical giant’s COVID-19 vaccine will cost less than €10 and revealed plans to list its drugs ingredients unit in the next few months.

Olivier Bogillot, Sanofi’s chief in France, told France Inter radio on Saturday that the company’s coronavirus vaccine candidate, being developed in partnership with Britain’s GlaxoSmithKline GSK, -1.38%, was likely to be priced at less than €10 per shot but that a final price had not been set.

The potential vaccine, a slower effort than many of its peers, began human trials earlier this month, and it is hoped regulatory approval will be reached in the first half of next year.

Read: Sanofi looks to accelerate MS treatment with $3.68 billion Principia Biopharma acquisition

In the meantime, Sanofi is set to publicly list its active pharmaceutical ingredients (API) company, with an initial public offering planned in the coming months, Bogillot told France Inter radio. “The idea is to create a champion of active ingredients at the European level,” he said. The business could be valued at between €1 billion and €2 billion, sources told Reuters in July.

Sanofi announced plans in February to create a standalone company making API by combining its commercial and development activities with six of its production sites in Europe.

The French drugmaker said at the time it would decide whether to list the new company on Euronext Paris by 2022. It would be the world’s second largest API company, behind Switzerland’s Lonza LONN, +3.26%, with approximately €1 billion in expected sales by 2022, Sanofi said earlier this year.

The company said the spin off would help balance the industry’s “heavy reliance” on Asia for drug ingredients, which was highlighted through the disruption at the beginning of the coronavirus pandemic.

Filed in: Top News Tags: 

You might like:

Asia Markets: Asian stocks mixed as investors wait for Wall Street to return from break Asia Markets: Asian stocks mixed as investors wait for Wall Street to return from break
The Moneyist: My partner has earned millions of dollars during our relationship. We’re not married, but am I entitled to anything if we split? The Moneyist: My partner has earned millions of dollars during our relationship. We’re not married, but am I entitled to anything if we split?
Outside the Box: The Trump administration wants to discourage your 401(k) from including ESG investment options Outside the Box: The Trump administration wants to discourage your 401(k) from including ESG investment options
Europe Markets: European stocks rally, diverging from U.S. tech slump Europe Markets: European stocks rally, diverging from U.S. tech slump
Dispatches from a Pandemic: Virology experts say the key is keeping Spain’s hospitals from becoming overwhelmed by COVID-19 this time Dispatches from a Pandemic: Virology experts say the key is keeping Spain’s hospitals from becoming overwhelmed by COVID-19 this time
The New York Post: Pyrotechnic device at gender-reveal party in California sparks wildfire The New York Post: Pyrotechnic device at gender-reveal party in California sparks wildfire
Some COVID-19 patients suffer lung and heart damage, but there’s encouraging news for these ‘long haulers’ Some COVID-19 patients suffer lung and heart damage, but there’s encouraging news for these ‘long haulers’
NewsWatch: This ‘Nasdaq whale’ may have helped trigger the stock-market’s brutal rout NewsWatch: This ‘Nasdaq whale’ may have helped trigger the stock-market’s brutal rout

Leave a Reply

Submit Comment
© 5617 Stock Investors News. All rights reserved. XHTML / CSS Valid.